Skip to main content
. Author manuscript; available in PMC: 2008 Mar 31.
Published in final edited form as: Am J Physiol Renal Physiol. 2005 Dec 27;290(5):F1024–F1033. doi: 10.1152/ajprenal.00221.2005

Fig. 2.

Fig. 2

Effects of angiotensin type 2 (AT2) and/or type 1 (AT1) receptor blockade on MAP and CBF and MBF responses to iv infusion of ANG IV (1 nmol ·kg−1 ·min−1). ANG IV increased MAP and decreased CBF. These responses were not altered by the AT2 receptor antagonist PD-123319 (PD) but were reversed by the AT1 receptor antagonist losartan (Los). P < 0.05 vs. control (*) and vs. ANG IV response (#).